10.66
+0.57%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China Medical System Holdings
Its shares trade on HKEX under the ticker 867.HK. It has been listed since 28 September 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥9.58bn and net income of CN¥1.74bn. At that date it held total assets of CN¥22.40bn and shareholders' equity of CN¥20.30bn.
China Medical System Holdings Ltd. engages in the production, marketing, promotion, and sale of drugs. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2010-09-28. Its main products under direct network include Deanxit, Ursofalk, XinHuoSu, Salofalk, Bioflor and Augentropfen Stulln Mono Eye-drops, among others. Its products under the agency promotion network include ShaDuoLiKa, YiNuoShu and XiDaKang, among others. The products of the Company are used in the treatment of gastropathy, cardiopathy, traumatic infection, hepatopathy and eye diseases, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Sept 2010
- Employees
- 4,052
- Website
- cms.net.cn ↗
Leadership
Pay as last reported
- Mr. Kong LamExecutive Chairman of the Board, President, Chief Executive OfficerCN¥6.2m
- Ms. Yanling ChenChief Financial Officer, Vice President, Executive DirectorCN¥4.9m
- Mr. Anjun HuangGeneral Manager - Dermatology and Medical Aesthetic Business Division
- Mr. Qingfu JiangGeneral Manager - Cardio-Cerebrovascular/Digestion Business Division
- Ms. Yufang LiGeneral Manager - Finance Center
- Mr. Lieyi MaGeneral Manager - Operations and Management Center
- Ms. Linlang WangGeneral Manager - Ophthalmology Business Division
- Mr. Ping CaiDeputy General Manager and General Manager - Strategic Market
- Mr. Jie FanDeputy General Manager and General Manager - Channel and Off Hospital Business
- Mr. Fei JiangChief Investment Officer (Greater China)
- Dr. Huaizheng PengChief Business Officer, since 2010
- Mr. James StearnsChief Investment Officer (Europe and America)
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 99
- Social
- 99
- Governance
- 66
- Direct emissions (scope 1)
- 1,549 t
- Energy emissions (scope 2)
- 3,999.1 t
- Value chain emissions (scope 3)
- 7,406.7 t
- Women in the workforce
- 55.3%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- China Medical System Holdings Ltd has several key strengths that contribute to its success in the market:
Weaknesses
- Despite its strengths, China Medical System also faces some weaknesses that may hinder its growth:
Opportunities
- There are several promising opportunities that China Medical System can leverage for future growth:
Threats
- China Medical System should also be aware of potential threats that could impact its business:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.